{
  "docId": "019de070-14f8-7659-9020-5924af9296cd",
  "docSlug": "a0353e82ff2da767329aa025539c408b",
  "documentTitle": "Legend Biotech | IPO Presentation Deck | 42 slides",
  "authorId": "legend-biotech",
  "authorName": "Legend Biotech",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 42,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Data from CARTITUDE-1 Phase 1b study presented at ASCO 2020.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-14f8-7659-9020-5924af9296cd/17",
  "deckHref": "/decks/019de070-14f8-7659-9020-5924af9296cd",
  "deckJsonHref": "/decks/019de070-14f8-7659-9020-5924af9296cd.json",
  "deckAnchorHref": "/decks/019de070-14f8-7659-9020-5924af9296cd#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.15,
        "x": 0.35,
        "y": 0.3
      },
      "kind": "callout",
      "text": "Median time to first response = 1 mo (1-3); Median time to CR = 3 mo (1-13); 81% of evaluable patients (n=16) were MRD negative at 10-5 or 10-6 at the time of first suspected CR",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41564ab3-2561-4466-b0a4-0dfb1894f667",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Objective Response Rate (N=29)",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1faabf93-3102-457c-bd49-32ef546b8858",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Tumor Burden Reduction",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44483254-fd26-42c2-a74a-0de3f9b99f32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "PR or better; Independent Review Committee-assessed; No patient had stable disease or progressive disease as best response. Serum M-protein, urine M-protein, or difference between involved and uninvolved free light chain (dFLC); Bence-Jones proteinuria at baseline, with a transient response during bridging therapy; output represents dFLC value; CR=complete response; MRD= minimal residual disease; ORR=overall response rate; NGS=next generation sequencing; PR=partial response; sCR=stringent complete response; VGPR=very good partial response; Berdeja et al. Abstract #8505 Presented at: 56th American Society of Clinical Oncology Annual Meeting 2020; May 29-31, 2020.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "912bd682-6da2-4eba-99e3-77aca4b50583",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "metric",
      "text": "ORR = 100%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e3d218e-fc36-45d8-bf37-75790b48e0ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.55,
        "y": 0.85
      },
      "kind": "metric",
      "text": "100% of patients achieved a reduction in Myeloma paraprotein",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e76fbb14-00a3-42ae-be50-8bf89509f9cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "CARTITUDE-1 (Ph 1b): Early, Deep Responses and High Response Rate",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2ef3228-67d2-407e-8e28-61c33339f4d7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "043a1aec-616c-40c2-b48f-c1b0d70a548d",
      "evidence": "chart/waterfall: Tumor Burden Reduction",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}